Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06051617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06051617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Recruiting
Start date
September 7, 2023
Completion date
August 31, 2030
Enrollment
402 (estimated)
Sites
217

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis